Related Experiment Video

Updated: Aug 6, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Hypertensive disorders of pregnancy contribute to developmental and metabolic multimorbidity in preterm infants

Cuihong Yang1,2, Ranran Shi1,2, Jiao Yuan3

  • 1Department of Neonatology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.

Nature Communications
|July 20, 2026
PubMed

Insights

Maternal hypertensive disorders of pregnancy (HDP) significantly increase very preterm infants

Area of Science:

  • Neonatal Health
  • Perinatal Medicine
  • Reproductive Biology

Background:

  • Preterm birth is a major global health concern, often leading to complex infant multimorbidity.
  • Maternal hypertensive disorders of pregnancy (HDP) are known to affect offspring, but their impact on specific multimorbidity patterns in very preterm infants is not well understood.

Purpose of the Study:

  • To systematically characterize distinct multimorbidity patterns in very preterm infants born to mothers with HDP.
  • To investigate the association between maternal HDP and the development of specific infant multimorbidity profiles.

Main Methods:

  • A multicenter cohort study utilizing the Sino-northern Neonatal Network (SNN) database.
  • Systematic characterization of multimorbidity patterns in very preterm infants.

Main Results:

  • Identified distinct multimorbidity patterns, including extrauterine growth restriction (EUGR) complicated by parenteral nutrition-associated cholestasis (EUGR-PNAC), congenital hypothyroidism (EUGR-CH), retinopathy of prematurity (EUGR-ROP), and bronchopulmonary dysplasia (EUGR-BPD).
  • Maternal HDP was found to significantly increase the risk of developing these specific multimorbidity patterns.

Conclusions:

  • Maternal HDP is a significant risk factor for specific multimorbidity patterns in very preterm infants.
  • Understanding these clinical consequences improves knowledge of intrauterine exposure effects on offspring health.
  • Highlights the need for multidisciplinary screening and management to improve long-term neonatal outcomes in high-risk populations.

More Related Videos

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...